Metsera Inc. (MTSR)
| Bid | n/a |
| Market Cap | 2.48B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.74M |
| EPS (ttm) | -2.03 |
| PE Ratio (ttm) | -11.65 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | n/a |
| Volume | 542,687 |
| Avg. Volume (20D) | 883,247 |
| Open | 24.27 |
| Previous Close | 24.11 |
| Day's Range | 22.61 - 24.35 |
| 52-Week Range | 12.30 - 32.81 |
| Beta | 0.00 |
About MTSR
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New Y...
Analyst Forecast
According to 4 analyst ratings, the average rating for MTSR stock is "Buy." The 12-month stock price forecast is $47, which is an increase of 98.69% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 DifferentiationMetsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing and a strong safety profile. Positive phase 2a results for MET-097i showed signific...
2 months ago · seekingalpha.com
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOsFive IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...